SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017 at 10:50 am ET. The conference will be held at the Lotte New York Palace, New York. The presentation will be webcast and available for replay in the Investor Section of Pfenex's website www.pfenex.com.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis, and PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged itsPfenex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, therapeutic equivalents to reference listed drug products, and next generation biologics.